title: [Anticoagulation in atrial fibrillation in the elderly: the geriatrician point of view with a focus on the direct oral anticoagulants].
abstract: Prescribing anticoagulant therapy when the CHA₂DS₂-VASc score is ≥ 1 prevents strokes secondary to non-valvular atrial fibrillation (AF). However, it is important to remember that whether the aged population has the highest risk of stroke in case of AF, under anticoagulant therapy this population is also at the highest risk of bleeding. Vitamin K antagonists were for decades the molecules of reference with benefits even after 75 years of age. The direct oral anticoagulants have overcome the biological constraints inherent to monitoring vitamin K antagonists and provide a more stable pharmacological action with a limited number of drug-drug interactions. However, the widespread use of these molecules in the older population remains controversial. In this review article, indications and modalities of administration of anticoagulant therapy in the elderly will be detailed and discussed on the basis of the most recent recommendations proposed in particular by the European Society of Cardiology. Particular attention will be paid to new oral anticoagulant therapies compared with vitamin K antagonists and antiplatelet agents.
authors.affiliation: Pôle de gériatrie, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France; EA 3072, institut de physiologie, faculté de médecine, université de Strasbourg, 67000 Strasbourg, France.
authors.forename: T
authors.initials: T
authors.lastname: Vogel
authors.affiliation: Pôle de gériatrie, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France; Département de physiologie et des explorations fonctionnelles, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France.
authors.forename: B
authors.initials: B
authors.lastname: Geny
authors.affiliation: Pôle de gériatrie, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France.
authors.forename: G
authors.initials: G
authors.lastname: Kaltenbach
authors.affiliation: Centre de médecine préventive Nescens, clinique de Genolier, route du Muids 3, 1272 Genolier, Suisse; Translational medicine research group, Cranfield health, Cranfield university, MK043 AL Cranfield, Angleterre. Electronic address: polang@nescens.com.
authors.forename: P-O
authors.initials: PO
authors.lastname: Lang
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D001291:Attitude of Health Personnel; D015577:Geriatric Assessment; D006801:Humans; D010820:Physicians; D012307:Risk Factors; D020521:Stroke / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control
chemical_list: D000925:Anticoagulants
keywords: Antivitamin K; Antivitamine K; Atrial fibrillation; Elderly; Fibrillation atriale; New oral anticoagulant; Nouveaux anticoagulants oraux; Sujet âgé